Solosec Granule
NDC Package 69751-400-01
Package Information
Solosec (secnidazole) granules is sOLOSEC is contraindicated:In patients who have shown hypersensitivity to secnidazole, or other nitroimidazole derivatives.In patients with Cockayne syndrome: Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole, another nitroimidazole drug, structurally related to secnidazole, in patients with Cockayne syndrome [see Adverse Reactions (6.2)]. This formulation utilizes a granule delivery system. Marketed by Evofem Inc., this product is identified by NDC 69751-400 and is authorized under FDA application NDA209363.
Identification & Billing
- RxCUI: 1946692 - secnidazole 2 GM Oral Granules
- RxCUI: 1946692 - secnidazole 2000 MG Oral Granules
- RxCUI: 1946698 - solosec 2 GM Oral Granules
- RxCUI: 1946698 - secnidazole 2000 MG Oral Granules [Solosec]
- RxCUI: 1946698 - Solosec 2 GM Oral Granules
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69751 - Evofem Inc.
- 69751-400 - Solosec
- 69751-400-01 - 1 PACKET in 1 CARTON / 2 g in 1 PACKET
- 69751-400 - Solosec
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69751-400-01 identifies a specific commercial package of 1 packet in 1 carton / 2 g in 1 packet of Solosec, a human prescription drug labeled by Evofem Inc.. This granule is formulated for oral use and contains secnidazole as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Evofem Inc. on May 31, 2018. The current certification is valid through December 31, 2027.
How is this Evofem Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69751040001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.